There have been suggestions that other biomarkers, such as hepcidin [51] and hemojuvelin [52], might improve the assessment of iron deficiency and responsive anemia, although this has not been borne out of trials using a targeted approach to supplementation with hepcidin [53]. This evidence concerns the gene HAMP and anemia.